CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced preliminary clinical data for investigational agent TP-3654 will be presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 10-13 in New Orleans, Louisiana. The data will be shared in an oral podium presentation during the Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis session on December 10 at 3:15 p.m. CST.
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration...
CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., (SMP Oncology) a clinical-stage company focused on research and development for novel cancer therapeutics, today announced it will present new clinical and preclinical data on a range of investigational agents from the company's pipeline at the American Association for Cancer Research (AACR) Annual Meeting, held April 8-13, 2022, in New Orleans, LA.
CAMBRIDGE, Mass., Dec. 14, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis. This study evaluated the safety and efficacy of Ombipepimut-S Emulsion (DSP-7888)*, an investigational WT1 immunotherapeutic cancer vaccine, in combination with bevacizumab versus bevacizumab alone in patients with recurrent or progressive glioblastoma (GBM) following initial therapy.
CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma.
CAMBRIDGE, Mass., Feb. 9, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS). Napabucasin in combination with FOLFIRI failed to show significant OS improvement in the general study population and in patients whose tumor was positive for the phosphorylated signal transducer and activator of transcription 3 (pSTAT3) biomarker.
CAMBRIDGE, Mass., Jan. 19, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).
CAMBRIDGE, Mass., Jan. 19, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).
When Lynn Seely took the helm at Myovant as the newly-retired chief medical officer of Medivation, the biotech was still a fledgling member of Vivek Ramaswamy’s sprawling Vant family, preparing to take flight with a Phase III drug from Takeda. Four and a half years later, everything has changed: Myovant’s largest shareholder is now Japanese pharma Sumitomo Dainippon, and in just the past month, the FDA handed relugolix its first approval and Pfizer has engineered a $4.2 billion commercial partnership.
CAMBRIDGE, Mass., Dec. 5, 2020 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in patients with MCL-1 dependent acute myeloid leukemia (AML). These results were presented at the 62nd American Society of Hematology Annual Meeting, being held virtually December 5-8, 2020.